Business Description
Olema Pharmaceuticals is a clinical-stage company dedicated to developing cancer treatments specifically for women. Its lead drug, palazestrant, works by blocking and breaking down estrogen receptors, and is currently being tested in a major Phase 3 trial for a common and difficult-to-treat form of breast cancer. The company is also running earlier-stage trials combining palazestrant with other targeted therapies, as well as testing a separate drug called OP-3136 in patients with breast and other solid tumors. Founded in 2006 and based in San Francisco, Olema is working to build a pipeline of meaningful treatments for women facing cancer.
